Takeda Pharmaceutical (TAK) Free Cash Flow (2018 - 2026)

Takeda Pharmaceutical has reported Free Cash Flow for 9 years, with the latest figure at $1.1 billion in Q2 2026.

• On a quarterly basis, Free Cash Flow fell 37.45% year-over-year to $1.1 billion in Q2 2026; TTM through Jun 2026 was $11.4 billion, a 32.52% increase from a year earlier, with the FY2026 full-year figure at $7.8 billion, down 6.0% from the prior year.
• Free Cash Flow was $1.1 billion for Q2 2026 at Takeda Pharmaceutical, up from $770.9 million in the prior quarter.
• The five-year high for Free Cash Flow was $6.8 billion in Q3 2025, with the low at $770.9 million in Q1 2026.
• Average Free Cash Flow over 5 years is $2.4 billion, with a median of $1.8 billion recorded in 2025.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow plunged 57.81% in 2022, then jumped 208.5% in 2025.
• Over 5 years, Free Cash Flow stood at $2.9 billion in 2022, then plunged by 55.07% to $1.3 billion in 2023, then jumped by 115.45% to $2.8 billion in 2024, then declined by 4.43% to $2.7 billion in 2025, then sank by 57.78% to $1.1 billion in 2026.
• The last three Free Cash Flow figures came in at $1.1 billion (Q2 2026), $770.9 million (Q1 2026), and $2.7 billion (Q4 2025), per Business Quant data.